Colonic Diseases  >>  Opdivo (nivolumab)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Opdivo (nivolumab) / BMS
MDX1106-01, NCT00441337: A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

Checkmark From Checkmate-003 for NSCLC at ASCO 2014
Jun 2014 - Jun 2014: From Checkmate-003 for NSCLC at ASCO 2014
Checkmark From Checkmate-003 for melanoma at ASCO 2014
Jun 2014 - Jun 2014: From Checkmate-003 for melanoma at ASCO 2014
Checkmark
More
Completed
1
39
US
MDX-1106, nivolumab
Bristol-Myers Squibb
Carcinoma, Non-Small-Cell Lung, Colorectal Cancer, Malignant Melanoma, Renal Cancer, Prostate Cancer
11/09
11/09
NCT02991196: Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer

Terminated
1
4
US
DS-8273a + nivolumab
Daiichi Sankyo, Inc., Bristol-Myers Squibb
Colorectal Neoplasm
09/17
09/17

Download Options